From the 20th to the 23rd September 2017, it will take place in Bruges, Belgium, the ISDS meeting.
The ISDS is registered as a non-profit organization and the principal aim of the Society is to promote scientific progress in the field of skeletal dysplasias and dysostoses. To this aim, the society organizes meetings on a two-year basis.
The focus of the meeting will be on the clinical, radiographic and molecular aspects of rare and genetic disorders of the skeleton with special attention to the newest discoveries within this field.
Clinicians and researchers with interest in rare bone disorders will attend this meeting, as representatives from industry and patient groups.
The themes related to achondroplasia that will be presented during the course of the three days meeting will be:
- Longitudinal bone growth velocity assessment by near-infrared imaging in a murine model of achondroplasia, by Florence Authier
- Achondroplasia natural history: the power of a multi-center clinical study, by Julie Hoover-Fong
- Disruptive, targeted emerging therapies in skeletal dysplasias, by Robin Forbes
- Oral administration of meclozine for the treatment of short stature in achondroplasia, by Hiroshi Kitoh
- FLAG-sFGFR3 treatment prevents the metabolic deregulations in achondroplasia, by Celine Saint-Laurent
And also, in a specific session “Treatment: ready for patients?”, Adrian Quartel, from BioMarin Corporate, will present “Who we are, what we do”.
There will also be posters presentation, with more than 50 posters submitted. The most relevant titles by now for achondroplasia are:
- How occupational therapy intervention within a multidisciplinary bone dysplasia clinic can promote functional independence for children with skeletal dysplasia, by Jennifer Robin
- Patient and public involvement (PPI) in designing clinical trials for rare diseases – the achondroplasia experience, by Emma Glass.
Insights of the meeting will be presented here after.